Hub : Traits :

Depressed Affect (Nagel 2018)

690 significantly associated models · 109 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	7715776	9571422	2	1	3.3e-08	1.8e-08	1.0e+00	100	RP5-1115A15.1
2	1	86635245	88508392	2	2	1.7e-07	3.1e-06	2.4e-02	77	LMO4 SEP15
3	1	242590540	244112606	1	1	2.7e-07	1.6e-06	4.1e-01	97	CEP170
4	2	23453834	25141538	4	1	1.3e-11	5.4e-11	9.0e-03	84	UBXN2A
5	2	147993969	149475737	2	1	7.1e-08	9.5e-10	2.4e-03	76	ORC4L
6	2	202952678	204421284	1	1	2.3e-07	2.2e-06	6.0e-01	99	ICA1L
7	2	219863589	220358586	2	1	4.9e-08	3.7e-07	7.4e-02	88	GLB1L
8	3	16154636	17814553	1	1	8.2e-08	3.3e-10	1.5e-04	64	PLCL2
9	3	48335857	50800146	22	1	8.3e-15	4.2e-10	3.0e-01	97	GPX1
10	3	135806811	136715468	1	1	1.1e-09	2.6e-09	1.0e+00	100	STAG1
11	5	87104604	88677293	1	1	8.9e-08	1.9e-09	6.4e-03	79	LINC00461
12	5	119109286	120721018	1	1	7.4e-09	1.7e-08	1.0e+00	100	PRR16
13	7	1580921	2977732	1	1	6.9e-08	6.3e-08	3.5e-03	71	FTSJ2
14	7	11553163	12967449	1	1	1.2e-10	5.1e-11	1.0e+00	100	TMEM106B
15	8	21720054	22214508	1	1	2.8e-08	8.4e-06	6.8e-01	99	NUDT18
16	8	141421996	142253369	1	1	1.9e-07	6.6e-07	8.7e-01	100	PTK2
17	9	95502571	96898436	1	1	9.7e-08	3.9e-08	1.2e-05	37	RP11-165J3.6
18	9	119768572	121177842	1	1	5.9e-10	2.3e-09	1.8e-02	84	TLR4
19	11	12611333	14105497	1	1	6.6e-08	6.1e-07	8.0e-01	100	ARNTL
20	11	46010847	48559571	18	8	1.9e-15	6.0e-14	NaN	NaN	ARHGAP1 C1QTNF4 LRP4 MADD NUP160
21	11	112135760	113969669	5	2	9.1e-14	1.8e-13	1.0e+00	100	DRD2 RP11-159N11.4
22	12	109295508	110704487	2	1	4.3e-08	5.1e-09	3.9e-02	88	MMAB
23	13	66643767	68053176	1	1	2.3e-08	1.9e-06	1.1e-04	34	PCDH9
24	14	74531485	76089054	3	1	1.0e-09	2.1e-10	6.6e-02	92	DLST
25	15	77207277	78806023	1	1	3.1e-07	3.8e-10	2.3e-05	54	LINGO1
26	16	70624483	72022941	1	1	2.2e-07	2.3e-06	3.5e-01	96	CMTR2
27	16	88523815	89030118	1	1	1.5e-07	9.9e-07	2.5e-01	94	CTU2
28	17	42607368	45796313	20	1	1.1e-22	1.4e-21	9.3e-02	97	WNT3
29	17	78843139	79380547	1	1	1.4e-07	4.0e-07	1.0e+00	100	AATK
30	18	34614002	35378540	1	1	1.1e-07	3.5e-12	5.6e-06	57	CELF4
31	18	49172179	51753106	1	1	2.5e-08	3.9e-12	4.3e-06	56	DCC
32	18	52209411	54028036	1	1	1.9e-08	8.3e-17	8.1e-15	13	TCF4
33	19	32151452	33668090	2	1	2.1e-11	1.1e-10	1.0e+00	100	DPY19L3
34	20	43958786	45456440	2	2	9.4e-11	1.8e-11	1.0e+00	100	CD40 SLC12A5
35	22	38388203	39770597	1	1	6.6e-08	1.9e-07	1.0e+00	100	TOMM22

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder or Schizophrenia	2.14	4	0	0.0	0.81	1.9e-01	ARHGAP1 CEP170 DCC SLC12A5
Depression (Nagel 2018)	9.33	17	3	6.7	0.98	4.4e-12	AATK C1QTNF4 CMTR2 DCC DPY19L3 FTSJ2 MADD NUP160 PCDH9 RP11-159N11.4 RP11-165J3.6 RP5-1115A15.1 SLC12A5 STAG1 TMEM106B UBXN2A WNT3
Intelligence (Savage-Jansen 2018)	3.18	8	6	13.3	-0.07	8.5e-01	AATK C1QTNF4 GPX1 LINC00461 NUP160 PLCL2 STAG1 WNT3
Neuroticism (Nagel 2018)	15.53	39	30	66.7	0.99	8.2e-33	AATK ARHGAP1 ARNTL C1QTNF4 CD40 CELF4 CMTR2 CTU2 DCC DLST DPY19L3 DRD2 FTSJ2 GPX1 LINC00461 LINGO1 LMO4 LRP4 MADD MMAB NUDT18 NUP160 ORC4L PCDH9 PLCL2 PRR16 PTK2 RP11-159N11.4 RP11-165J3.6 RP5-1115A15.1 SEP15 SLC12A5 STAG1 TCF4 TLR4 TMEM106B TOMM22 UBXN2A WNT3
Schizophrenia (2018)	2.46	4	0	0.0	0.04	9.6e-01	ARHGAP1 DCC RP5-1115A15.1 STAG1
Schizophrenia vs Biploar Disorder	2.90	3	0	0.0	0.00	1.0e+00	ARHGAP1 ARNTL ICA1L
Worry (Nagel 2018)	8.52	16	10	22.2	0.99	1.6e-13	AATK ARNTL C1QTNF4 DLST DRD2 MADD MMAB NUP160 ORC4L PLCL2 RP11-159N11.4 RP11-165J3.6 SLC12A5 STAG1 TMEM106B WNT3
Alzheimer’s Disease (including proxy)	2.25	2	0	0.0	0.00	1.0e+00	C1QTNF4 MADD
Crohns Disease (2017)	1.58	3	1	2.2	0.00	1.0e+00	CD40 GPX1 SLC12A5
Irritable Bowel Disease (IBD)	1.55	3	1	2.2	0.00	1.0e+00	CD40 GPX1 SLC12A5
Ulcerative Colitis (UC)	1.21	1	1	2.2	0.00	1.0e+00	GPX1
Major Depression (MDD)	4.07	3	0	0.0	0.00	1.0e+00	GPX1 TCF4 TMEM106B
Reaction Time	3.06	2	1	2.2	-0.99	1.1e-02	ARHGAP1 LRP4
Verbal and Numeric Reasoning (VNR)	2.79	5	1	2.2	0.14	7.9e-01	C1QTNF4 GPX1 LINC00461 NUP160 STAG1
Breast Cancer	1.26	1	1	2.2	0.00	1.0e+00	WNT3
Ovarian Cancer	1.26	1	1	2.2	0.00	1.0e+00	WNT3
Prostate Cancer	1.76	1	0	0.0	0.00	1.0e+00	GPX1
Age at First Birth	2.02	1	1	2.2	0.00	1.0e+00	GPX1
Body Mass Index (BMI) (2010)	2.89	2	1	2.2	0.00	1.0e+00	C1QTNF4 MADD
Coronary Artery Disease (CAD)	1.87	1	0	0.0	0.00	1.0e+00	ICA1L
Mean Putamen Volume	1.38	1	0	0.0	0.00	1.0e+00	WNT3
Fasting Glucose	2.31	2	1	2.2	0.00	1.0e+00	LRP4 MADD
HDL Cholesterol	3.74	6	3	6.7	0.09	8.3e-01	ARHGAP1 C1QTNF4 DPY19L3 LRP4 MMAB NUP160
LDL Cholesterol	1.66	1	0	0.0	0.00	1.0e+00	CMTR2
Neuroticism (2016)	8.04	10	2	4.4	0.98	3.8e-08	C1QTNF4 CELF4 DRD2 GPX1 LINC00461 MADD PCDH9 TCF4 TLR4 WNT3
Primary Biliary Cirrhosis	1.68	2	0	0.0	0.00	1.0e+00	PLCL2 WNT3
Rheumatoid Arthritis	2.10	2	0	0.0	0.00	1.0e+00	CD40 SLC12A5
Schizophrenia (2014)	2.72	5	1	2.2	-0.12	8.5e-01	ARHGAP1 CEP170 DRD2 RP5-1115A15.1 STAG1
Triglycerides	1.64	1	0	0.0	0.00	1.0e+00	LRP4
Ulcerative Colitis	1.31	1	1	2.2	0.00	1.0e+00	GPX1
Blood Eosinophil Count	1.38	5	3	6.7	-0.94	1.6e-02	GPX1 ORC4L PLCL2 RP5-1115A15.1 WNT3
Blood Platelet Count	1.03	8	5	11.1	0.50	1.7e-01	C1QTNF4 DLST LINC00461 LRP4 MADD PTK2 TOMM22 WNT3
Blood Red Count	1.87	7	4	8.9	0.28	5.4e-01	ARNTL CMTR2 CTU2 DRD2 LINC00461 UBXN2A WNT3
Blood White Count	1.83	9	6	13.3	-0.05	9.0e-01	AATK C1QTNF4 GPX1 LINC00461 MADD NUP160 RP5-1115A15.1 UBXN2A WNT3
Heel T-Score	4.54	7	6	13.3	-0.69	4.0e-02	ARHGAP1 DLST LRP4 MADD RP5-1115A15.1 TOMM22 WNT3
BMI	3.73	10	6	13.3	-0.22	5.2e-01	ARNTL C1QTNF4 CEP170 FTSJ2 GPX1 LINC00461 MADD NUP160 RP11-159N11.4 TLR4
Height	1.73	19	17	37.8	-0.08	7.4e-01	AATK C1QTNF4 CMTR2 CTU2 DCC FTSJ2 GLB1L GPX1 LRP4 MADD NUP160 ORC4L RP11-165J3.6 RP5-1115A15.1 STAG1 TCF4 TMEM106B UBXN2A WNT3
Waist Hip Ratio (WHR)	1.45	6	3	6.7	-0.03	9.5e-01	GPX1 PTK2 RP11-159N11.4 STAG1 UBXN2A WNT3
Systolic Blood Pressure	3.17	10	6	13.3	0.49	1.0e-01	ARHGAP1 ARNTL C1QTNF4 CMTR2 GPX1 LRP4 MADD ORC4L PTK2 RP5-1115A15.1
Smoking Status	2.95	5	2	4.4	0.09	8.9e-01	AATK GPX1 NUP160 RP5-1115A15.1 WNT3
Allergy or Eczema	1.77	3	1	2.2	0.00	1.0e+00	PLCL2 RP5-1115A15.1 SLC12A5
Cardiovascular Disease	1.85	5	0	0.0	0.14	8.2e-01	ARNTL FTSJ2 NUDT18 RP11-159N11.4 RP5-1115A15.1
Hypothyroidism (self reported)	1.46	2	1	2.2	0.00	1.0e+00	C1QTNF4 RP5-1115A15.1
Respiratory disease	1.56	1	1	2.2	0.00	1.0e+00	RP5-1115A15.1
Type 2 Diabetes (T2D) (2018)	1.21	1	0	0.0	0.00	1.0e+00	C1QTNF4
Lung FEV1/FVC ratio	0.88	3	1	2.2	0.00	1.0e+00	DLST PRR16 RP5-1115A15.1
Lung FVC	2.31	5	3	6.7	-0.73	1.6e-01	DCC GPX1 TCF4 UBXN2A WNT3
Neuroticism	14.57	38	29	64.4	0.99	1.0e-31	AATK ARHGAP1 ARNTL C1QTNF4 CD40 CELF4 CEP170 CMTR2 CTU2 DLST DPY19L3 DRD2 FTSJ2 GPX1 ICA1L LINC00461 LINGO1 LRP4 MADD MMAB NUDT18 NUP160 ORC4L PCDH9 PLCL2 PRR16 PTK2 RP11-159N11.4 RP11-165J3.6 RP5-1115A15.1 SEP15 SLC12A5 STAG1 TCF4 TLR4 TMEM106B UBXN2A WNT3
Chronotype (morning person)	1.85	1	0	0.0	0.00	1.0e+00	C1QTNF4
Hair Pigment	0.26	4	2	4.4	-0.02	9.8e-01	CTU2 LRP4 RP5-1115A15.1 WNT3
Tanning	0.37	2	1	2.2	0.00	1.0e+00	C1QTNF4 CTU2
Hand grip strength (left)	2.88	5	4	8.9	-0.02	9.7e-01	C1QTNF4 LINGO1 MADD TCF4 WNT3
Number of treatments/medications taken	2.94	3	1	2.2	0.00	1.0e+00	DLST FTSJ2 GPX1
Sensitivity / hurt feelings	6.15	10	4	8.9	0.98	2.5e-07	CELF4 DRD2 MMAB ORC4L PLCL2 PTK2 RP11-159N11.4 RP11-165J3.6 STAG1 WNT3
Frequency of depressed mood in last 2 weeks	8.83	12	1	2.2	0.99	7.8e-10	AATK C1QTNF4 DRD2 MADD NUP160 PCDH9 RP11-165J3.6 RP5-1115A15.1 STAG1 TMEM106B UBXN2A WNT3
Hearing difficulty/problems: Yes	1.45	2	0	0.0	0.00	1.0e+00	MMAB PTK2
Relative age of first facial hair	2.17	1	1	2.2	0.00	1.0e+00	WNT3
Ever used hormone-replacement therapy (HRT)	2.31	1	0	0.0	0.00	1.0e+00	TOMM22
Systolic blood pressure, automated reading	2.29	5	3	6.7	0.34	5.7e-01	ARNTL GPX1 LRP4 MADD RP5-1115A15.1
Eye problems/disorders: Diabetes related eye disease	1.65	1	0	0.0	0.00	1.0e+00	C1QTNF4
Medication: Metformin	1.80	1	0	0.0	0.00	1.0e+00	C1QTNF4
Pack years adult smoking proportion	2.50	2	0	0.0	0.00	1.0e+00	CELF4 GPX1
Impedance of leg (right)	1.60	6	4	8.9	0.11	8.4e-01	C1QTNF4 GPX1 LINC00461 MADD STAG1 UBXN2A
Leg fat-free mass (left)	1.22	3	1	2.2	0.00	1.0e+00	ARHGAP1 C1QTNF4 LINC00461
Trunk fat percentage	3.93	13	6	13.3	-0.28	3.3e-01	ARNTL C1QTNF4 CEP170 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUDT18 NUP160 RP5-1115A15.1 UBXN2A WNT3
Hand grip strength (right)	2.20	6	3	6.7	-0.04	9.3e-01	C1QTNF4 LINGO1 LMO4 MADD TCF4 WNT3
Current tobacco smoking	3.26	5	1	2.2	0.71	1.1e-01	AATK C1QTNF4 CELF4 NUP160 RP5-1115A15.1
Fed-up feelings	11.49	26	12	26.7	0.99	1.1e-21	ARHGAP1 ARNTL CD40 CELF4 CMTR2 DCC DLST DPY19L3 DRD2 GPX1 LINC00461 LINGO1 LMO4 LRP4 MADD ORC4L PCDH9 PRR16 PTK2 RP11-159N11.4 SEP15 SLC12A5 STAG1 TLR4 UBXN2A WNT3
Frequency of unenthusiasm / disinterest in last 2 weeks	6.88	6	1	2.2	0.99	1.2e-04	DCC DRD2 PCDH9 RP11-159N11.4 STAG1 UBXN2A
Relative age voice broke	1.79	1	1	2.2	0.00	1.0e+00	WNT3
Taking other prescription medications	2.93	2	0	0.0	0.00	1.0e+00	DLST GPX1
Age when periods started (menarche)	2.94	5	4	8.9	1.00	3.6e-05	ARNTL C1QTNF4 GPX1 MADD NUP160
Heel bone mineral density (BMD) T-score, automated (left)	3.16	4	3	6.7	-0.80	5.9e-02	ARHGAP1 LRP4 RP5-1115A15.1 TOMM22
Qualifications: CSEs or equivalent	1.57	1	0	0.0	0.00	1.0e+00	WNT3
High blood pressure	2.37	5	2	4.4	0.46	3.6e-01	ARHGAP1 ARNTL LRP4 MADD RP5-1115A15.1
Hayfever, allergic rhinitis or eczema	1.65	1	1	2.2	0.00	1.0e+00	RP5-1115A15.1
Stomach or abdominal pain in last month	3.06	1	0	0.0	0.00	1.0e+00	STAG1
Medication: Atenolol	1.34	1	0	0.0	0.00	1.0e+00	ICA1L
Medication: Levothyroxine sodium	1.25	1	0	0.0	0.00	1.0e+00	RP5-1115A15.1
Sitting height	2.32	9	7	15.6	0.09	8.0e-01	AATK ARHGAP1 C1QTNF4 DCC LRP4 MADD NUP160 UBXN2A WNT3
Body mass index (BMI)	3.71	10	7	15.6	-0.16	6.4e-01	ARNTL C1QTNF4 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUP160 RP5-1115A15.1 STAG1
Impedance of leg (left)	1.58	8	3	6.7	-0.07	8.6e-01	C1QTNF4 FTSJ2 GPX1 LINC00461 MADD STAG1 UBXN2A WNT3
Leg predicted mass (left)	1.24	3	1	2.2	0.00	1.0e+00	ARHGAP1 C1QTNF4 LINC00461
Trunk fat mass	3.02	9	4	8.9	-0.33	3.5e-01	ARNTL C1QTNF4 CEP170 DPY19L3 GPX1 LINC00461 MADD RP5-1115A15.1 WNT3
Waist circumference	2.74	7	4	8.9	-0.14	7.4e-01	ARNTL C1QTNF4 DPY19L3 FTSJ2 LINC00461 MADD RP11-159N11.4
Past tobacco smoking	1.67	1	0	0.0	0.00	1.0e+00	WNT3
Alcohol usually taken with meals	2.21	1	1	2.2	0.00	1.0e+00	CELF4
Nervous feelings	5.37	7	3	6.7	0.99	2.1e-05	ARNTL C1QTNF4 DLST MADD ORC4L STAG1 WNT3
Frequency of tenseness / restlessness in last 2 weeks	6.99	11	3	6.7	0.99	3.6e-08	AATK C1QTNF4 DRD2 GPX1 MADD MMAB RP11-165J3.6 STAG1 TMEM106B UBXN2A WNT3
Hearing difficulty/problems with background noise	3.26	3	0	0.0	0.95	1.4e-02	ARHGAP1 LRP4 WNT3
Hair/balding pattern: Pattern 2	1.72	1	1	2.2	0.00	1.0e+00	WNT3
Forced vital capacity (FVC)	2.66	5	3	6.7	-0.07	9.0e-01	C1QTNF4 GPX1 LRP4 NUP160 WNT3
Heel bone mineral density (BMD) T-score, automated (right)	3.43	4	3	6.7	-0.76	8.1e-02	ARHGAP1 LRP4 RP5-1115A15.1 TOMM22
Ever unenthusiastic/disinterested for a whole week	2.60	1	0	0.0	0.00	1.0e+00	WNT3
Qualifications: None of the above	2.34	2	1	2.2	0.00	1.0e+00	CELF4 GPX1
Financial difficulties in last 2 years	2.76	1	0	0.0	0.00	1.0e+00	DRD2
Mouth/teeth dental problems	2.43	2	0	0.0	0.00	1.0e+00	CEP170 WNT3
Heart attack	1.66	1	0	0.0	0.00	1.0e+00	ICA1L
Allergy	1.53	1	1	2.2	0.00	1.0e+00	RP5-1115A15.1
Fluid intelligence score	2.88	5	3	6.7	0.32	5.4e-01	C1QTNF4 GPX1 MADD NUP160 STAG1
Neuroticism score	13.70	31	23	51.1	0.99	2.6e-27	AATK ARHGAP1 ARNTL C1QTNF4 CD40 CELF4 DLST DPY19L3 DRD2 FTSJ2 GPX1 LINC00461 LINGO1 LRP4 MADD MMAB NUP160 ORC4L PCDH9 PLCL2 PTK2 RP11-159N11.4 RP11-165J3.6 RP5-1115A15.1 SLC12A5 STAG1 TCF4 TLR4 TMEM106B UBXN2A WNT3
Weight	1.65	6	3	6.7	0.07	8.8e-01	C1QTNF4 CEP170 DPY19L3 GPX1 LINC00461 MADD
Impedance of arm (right)	1.46	5	3	6.7	-0.97	6.4e-03	GPX1 LINC00461 STAG1 TMEM106B WNT3
Arm fat percentage (right)	4.49	11	7	15.6	-0.25	4.3e-01	ARNTL C1QTNF4 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUDT18 NUP160 RP11-159N11.4 RP5-1115A15.1
Trunk fat-free mass	1.27	5	3	6.7	0.34	5.1e-01	ARHGAP1 C1QTNF4 LRP4 NUP160 UBXN2A
Hip circumference	2.12	8	4	8.9	0.10	7.9e-01	C1QTNF4 CEP170 DPY19L3 FTSJ2 GPX1 LINC00461 MADD TOMM22
Time employed in main current job	1.82	1	1	2.2	0.00	1.0e+00	WNT3
Alcohol intake versus 10 years previously	2.38	1	0	0.0	0.00	1.0e+00	FTSJ2
Father's age at death	1.78	1	0	0.0	0.00	1.0e+00	GPX1
Worrier / anxious feelings	5.67	10	4	8.9	0.98	4.4e-07	ARNTL DLST LINGO1 MMAB ORC4L RP11-165J3.6 STAG1 TCF4 TLR4 WNT3
Frequency of tiredness / lethargy in last 2 weeks	7.41	11	2	4.4	0.98	1.9e-08	AATK ARHGAP1 C1QTNF4 GPX1 MMAB ORC4L PTK2 RP11-165J3.6 RP5-1115A15.1 STAG1 UBXN2A
Hair/balding pattern: Pattern 3	2.31	1	1	2.2	0.00	1.0e+00	WNT3
Number of live births	1.59	1	0	0.0	0.00	1.0e+00	WNT3
Forced expiratory volume in 1-second (FEV1)	2.56	4	2	4.4	-0.93	2.4e-02	C1QTNF4 GPX1 UBXN2A WNT3
Pulse rate	1.50	2	1	2.2	0.00	1.0e+00	SEP15 TOMM22
Qualifications: A levels/AS levels or equivalent	2.36	2	1	2.2	0.00	1.0e+00	GPX1 LINC00461
Mouth/teeth dental problems: Dentures	1.65	2	0	0.0	0.00	1.0e+00	GPX1 STAG1
Asthma	1.50	1	1	2.2	0.00	1.0e+00	RP5-1115A15.1
Medication: Ibuprofen (e.g. Nurofen)	2.00	1	0	0.0	0.00	1.0e+00	UBXN2A
Depression (self-reported)	3.59	2	0	0.0	0.00	1.0e+00	RP5-1115A15.1 TMEM106B
Forced expiratory volume in 1-second (FEV1), Best measure	2.63	3	3	6.7	-0.97	2.5e-02	C1QTNF4 GPX1 WNT3
Impedance of arm (left)	1.50	3	3	6.7	0.00	1.0e+00	GPX1 STAG1 WNT3
Arm fat mass (right)	3.39	10	6	13.3	-0.22	5.1e-01	ARNTL C1QTNF4 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUP160 RP11-159N11.4 RP5-1115A15.1
Trunk predicted mass	1.25	5	3	6.7	0.34	5.1e-01	ARHGAP1 C1QTNF4 LRP4 NUP160 UBXN2A
Standing height	1.94	14	9	20.0	-0.07	8.1e-01	AATK C1QTNF4 FTSJ2 GLB1L GPX1 LRP4 MADD NUP160 RP11-165J3.6 RP5-1115A15.1 STAG1 TMEM106B UBXN2A WNT3
Tense / 'highly strung'	4.65	7	3	6.7	0.98	1.2e-04	AATK DRD2 ORC4L RP11-159N11.4 RP11-165J3.6 RP5-1115A15.1 TMEM106B
Seen doctor (GP) for nerves, anxiety, tension or depression	5.70	7	3	6.7	0.96	4.9e-04	CELF4 DRD2 FTSJ2 GPX1 SLC12A5 TCF4 TMEM106B
Hair/balding pattern: Pattern 4	3.55	2	1	2.2	0.00	1.0e+00	RP5-1115A15.1 WNT3
Peak expiratory flow (PEF)	1.75	2	1	2.2	0.00	1.0e+00	C1QTNF4 WNT3
Qualifications: O levels/GCSEs or equivalent	2.28	3	1	2.2	0.00	1.0e+00	GPX1 LINC00461 PLCL2
Medication: Paracetamol	3.36	3	3	6.7	0.00	1.0e+00	CEP170 GPX1 WNT3
Headache pain in last month	3.81	5	2	4.4	0.99	8.3e-04	CEP170 LMO4 NUDT18 TLR4 WNT3
Hypothyroidism/myxoedema (self-reported)	1.23	1	0	0.0	0.00	1.0e+00	RP5-1115A15.1
Birth weight	1.08	1	0	0.0	0.00	1.0e+00	C1QTNF4
Forced vital capacity (FVC), Best measure	2.99	5	3	6.7	-0.26	5.7e-01	C1QTNF4 GPX1 LRP4 NUP160 WNT3
Body fat percentage	4.07	13	6	13.3	-0.24	4.1e-01	ARNTL C1QTNF4 CEP170 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUDT18 NUP160 RP5-1115A15.1 UBXN2A WNT3
Leg fat percentage (right)	3.71	11	5	11.1	-0.12	7.1e-01	ARNTL C1QTNF4 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUDT18 NUP160 RP5-1115A15.1 UBXN2A
Arm fat-free mass (right)	1.06	3	0	0.0	0.00	1.0e+00	GPX1 LINC00461 NUP160
Comparative body size at age 10	3.20	5	4	8.9	-0.82	4.6e-02	C1QTNF4 LINC00461 MADD NUP160 RP11-165J3.6
Number of full brothers	1.80	1	0	0.0	0.00	1.0e+00	WNT3
Worry too long after embarrassment	5.06	7	3	6.7	0.92	3.7e-03	ARNTL DRD2 LINC00461 MMAB RP11-159N11.4 STAG1 WNT3
Seen a psychiatrist for nerves, anxiety, tension or depression	3.40	1	0	0.0	0.00	1.0e+00	TMEM106B
Wheeze or whistling in the chest in last year	2.24	3	0	0.0	0.00	1.0e+00	GPX1 RP11-165J3.6 RP5-1115A15.1
Age at first live birth	2.52	2	1	2.2	0.00	1.0e+00	CELF4 GPX1
Health satisfaction	3.22	3	0	0.0	0.00	1.0e+00	DRD2 GPX1 PCDH9
Qualifications: College or University degree	2.89	6	5	11.1	-0.42	4.1e-01	CELF4 CEP170 FTSJ2 GPX1 LINC00461 WNT3
Emphysema/chronic bronchitis	1.72	1	0	0.0	0.00	1.0e+00	WNT3
Medication for pain relief, constipation, heartburn	3.05	5	1	2.2	-0.97	7.4e-03	CEP170 GPX1 PCDH9 RP11-165J3.6 WNT3
Neck or shoulder pain in last month	3.20	2	0	0.0	0.00	1.0e+00	GPX1 RP5-1115A15.1
Mean time to correctly identify matches	3.15	2	2	4.4	-0.99	9.8e-03	ARHGAP1 LRP4
Whole body fat mass	3.12	10	5	11.1	-0.16	6.4e-01	ARNTL C1QTNF4 CEP170 DPY19L3 FTSJ2 GPX1 LINC00461 MADD RP11-159N11.4 RP5-1115A15.1
Leg fat mass (right)	3.16	10	5	11.1	-0.12	7.3e-01	ARNTL C1QTNF4 CEP170 DPY19L3 FTSJ2 GPX1 LINC00461 MADD RP11-159N11.4 RP5-1115A15.1
Arm predicted mass (right)	1.06	4	0	0.0	0.65	3.5e-01	GPX1 LINC00461 LRP4 NUP160
Pulse rate, automated reading	1.67	4	1	2.2	-0.99	7.1e-03	LINC00461 LMO4 ORC4L TOMM22
Alcohol intake frequency.	3.84	7	4	8.9	-0.09	8.3e-01	C1QTNF4 DCC DRD2 MADD RP11-159N11.4 TCF4 WNT3
Comparative height size at age 10	1.86	11	7	15.6	-0.30	3.7e-01	C1QTNF4 CMTR2 DLST GLB1L GPX1 LRP4 NUP160 RP5-1115A15.1 STAG1 TCF4 WNT3
Suffer from 'nerves'	8.27	8	4	8.9	0.95	3.6e-05	AATK ARHGAP1 C1QTNF4 DLST MADD NUP160 RP5-1115A15.1 WNT3
Overall health rating	4.38	7	3	6.7	0.99	3.9e-06	AATK CEP170 GPX1 NUDT18 PTK2 RP11-159N11.4 RP11-165J3.6
Age at last live birth	1.80	1	1	2.2	0.00	1.0e+00	GPX1
Leg pain on walking	2.09	1	0	0.0	0.00	1.0e+00	WNT3
Supplements: Vitamin C	1.41	1	0	0.0	0.00	1.0e+00	WNT3
Hypertension (Self-reported)	2.19	5	1	2.2	0.42	4.1e-01	ARHGAP1 ARNTL LRP4 MADD RP5-1115A15.1
Illnesses of father: Heart disease	1.34	2	0	0.0	0.00	1.0e+00	ICA1L WNT3
Forced expiratory volume in 1-second (FEV1), predicted	1.58	1	0	0.0	0.00	1.0e+00	C1QTNF4
Whole body fat-free mass	1.10	6	0	0.0	0.30	5.1e-01	ARHGAP1 GPX1 LINC00461 LRP4 NUP160 UBXN2A
Leg fat-free mass (right)	1.21	4	1	2.2	-0.38	6.2e-01	ARHGAP1 C1QTNF4 LINC00461 LRP4
Arm fat percentage (left)	4.77	9	8	17.8	-0.40	2.6e-01	ARNTL C1QTNF4 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUP160 RP5-1115A15.1
Handedness (chirality/laterality): Left-handed	1.84	1	1	2.2	0.00	1.0e+00	WNT3
Mood swings	11.70	24	12	26.7	0.99	9.5e-20	C1QTNF4 CD40 CELF4 CMTR2 DCC DLST DPY19L3 DRD2 GLB1L GPX1 LRP4 MADD NUP160 PLCL2 PRR16 PTK2 RP11-159N11.4 RP11-165J3.6 SLC12A5 STAG1 TCF4 TLR4 TMEM106B WNT3
Loneliness, isolation	9.37	11	5	11.1	0.98	6.0e-08	C1QTNF4 GPX1 MADD NUDT18 NUP160 ORC4L PCDH9 RP5-1115A15.1 STAG1 TMEM106B WNT3
Mouth/teeth dental problems: Mouth ulcers	1.90	1	1	2.2	0.00	1.0e+00	WNT3
Back pain experienced in last month	3.12	1	0	0.0	0.00	1.0e+00	PTK2
Asthma (self-reported)	1.42	1	1	2.2	0.00	1.0e+00	RP5-1115A15.1
Smoking status: Current	3.12	3	1	2.2	1.00	3.5e-03	AATK C1QTNF4 NUP160
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.50	1	1	2.2	0.00	1.0e+00	WNT3
Whole body water mass	1.09	7	0	0.0	0.36	3.7e-01	ARHGAP1 DPY19L3 GPX1 LINC00461 LRP4 NUP160 UBXN2A
Leg predicted mass (right)	1.22	4	1	2.2	-0.38	6.2e-01	ARHGAP1 C1QTNF4 LINC00461 LRP4
Arm fat mass (left)	3.46	10	5	11.1	-0.25	4.6e-01	ARNTL C1QTNF4 CEP170 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUP160 RP5-1115A15.1
Number of self-reported non-cancer illnesses	3.39	4	1	2.2	0.58	4.2e-01	ARNTL FTSJ2 LRP4 TMEM106B
Average weekly champagne plus white wine intake	1.94	1	0	0.0	0.00	1.0e+00	WNT3
Miserableness	12.98	27	13	28.9	0.99	7.1e-24	ARHGAP1 ARNTL C1QTNF4 CD40 CELF4 DPY19L3 DRD2 FTSJ2 GPX1 ICA1L LINGO1 LMO4 LRP4 MADD MMAB NUP160 ORC4L PCDH9 RP11-159N11.4 RP11-165J3.6 RP5-1115A15.1 SLC12A5 STAG1 TCF4 TMEM106B UBXN2A WNT3
Guilty feelings	7.51	11	5	11.1	0.97	6.9e-07	AATK ARNTL C1QTNF4 CD40 DLST DRD2 LINGO1 MADD RP11-159N11.4 UBXN2A WNT3
Financial situation satisfaction	2.85	1	1	2.2	0.00	1.0e+00	GPX1
Medication: Paracetamol	2.99	3	1	2.2	0.00	1.0e+00	CEP170 GPX1 WNT3
Illnesses of father: High blood pressure	1.66	1	0	0.0	0.00	1.0e+00	MADD
Alcohol drinker status: Never	2.00	1	0	0.0	0.00	1.0e+00	C1QTNF4
Ever smoked	1.99	1	0	0.0	0.00	1.0e+00	AATK
Basal metabolic rate	1.11	5	1	2.2	0.49	4.0e-01	ARHGAP1 DPY19L3 GPX1 LINC00461 LRP4
Leg fat percentage (left)	3.87	10	6	13.3	-0.19	5.8e-01	ARNTL C1QTNF4 DPY19L3 GPX1 LINC00461 MADD NUDT18 NUP160 RP5-1115A15.1 UBXN2A
Arm fat-free mass (left)	1.08	4	1	2.2	1.00	3.7e-03	DPY19L3 GPX1 LINC00461 NUP160
Number of operations (self-reported)	2.30	2	0	0.0	0.00	1.0e+00	GPX1 RP5-1115A15.1
Average weekly beer plus cider intake	2.31	1	0	0.0	0.00	1.0e+00	CELF4
Irritability	6.49	12	4	8.9	0.98	2.3e-08	CELF4 CMTR2 DRD2 FTSJ2 GPX1 LINC00461 MMAB ORC4L TCF4 TLR4 TMEM106B WNT3
Fractured/broken bones in last 5 years	2.08	1	0	0.0	0.00	1.0e+00	WNT3
Diastolic blood pressure, automated reading	2.42	7	4	8.9	0.27	5.6e-01	ARNTL CEP170 GPX1 ICA1L LINC00461 MADD RP5-1115A15.1
Myopia	1.89	1	0	0.0	0.00	1.0e+00	FTSJ2
Vascular/heart problems diagnosed by doctor	2.31	5	1	2.2	-0.41	4.2e-01	ARHGAP1 ARNTL LRP4 MADD RP5-1115A15.1
Pain experienced in last month	3.85	4	1	2.2	-0.95	5.1e-02	GPX1 MMAB PTK2 WNT3
Heart attack/myocardial infarction (self-reported)	1.59	1	0	0.0	0.00	1.0e+00	ICA1L
Pack years of smoking	2.35	2	0	0.0	0.00	1.0e+00	CELF4 GPX1
Impedance of whole body	1.43	5	4	8.9	-0.70	1.9e-01	GPX1 LINC00461 STAG1 UBXN2A WNT3
Leg fat mass (left)	3.29	10	5	11.1	-0.20	5.6e-01	ARNTL C1QTNF4 CEP170 DPY19L3 FTSJ2 GPX1 LINC00461 MADD NUP160 RP5-1115A15.1
Arm predicted mass (left)	1.06	4	1	2.2	0.99	8.0e-03	DPY19L3 GPX1 LINC00461 NUP160

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	15	0.43	2.1
GTEx	Adipose Visceral Omentum	12	0.59	2.3
GTEx	Adrenal Gland	7	0.48	2.1
GTEx	Artery Aorta	11	0.37	2.2
GTEx	Artery Coronary	11	0.93	2.6
GTEx	Artery Tibial	14	0.37	2.1
GTEx	Brain Caudate basal ganglia	10	1.08	2.4
GTEx	Brain Cerebellar Hemisphere	10	0.67	2.3
GTEx	Brain Cerebellum	11	0.55	2.3
GTEx	Brain Cortex	12	1.16	2.5
GTEx	Brain Frontal Cortex BA9	7	0.76	2.5
GTEx	Brain Hippocampus	6	1.15	2.6
GTEx	Brain Hypothalamus	6	1.02	2.6
GTEx	Brain Nucleus accumbens basal ganglia	7	0.81	2.4
GTEx	Brain Putamen basal ganglia	5	0.80	2.5
GTEx	Breast Mammary Tissue	11	0.56	2.3
GTEx	Breast Mammary Tissue (Male)	7	0.59	2.2
GTEx	Breast Mammary Tissue (Female)	11	0.67	2.3
GTEx	Cells EBV-transformed lymphocytes	13	0.92	2.4
GTEx	Cells Transformed fibroblasts	21	0.50	2.1
GTEx	Colon Sigmoid	10	0.68	2.3
GTEx	Colon Transverse	10	0.48	2.2
GTEx	Esophagus Gastroesophageal Junction	14	0.97	2.5
GTEx	Esophagus Mucosa	16	0.48	2.2
GTEx	Esophagus Muscularis	19	0.59	2.2
GTEx	Heart Atrial Appendage	10	0.63	2.2
GTEx	Heart Left Ventricle	9	0.59	2.3
GTEx	Liver	6	0.84	2.3
GTEx	Lung	18	0.63	2.2
GTEx	Muscle Skeletal	11	0.38	2.1
GTEx	Nerve Tibial	13	0.30	2.0
GTEx	Ovary	9	0.99	2.6
GTEx	Pancreas	8	0.49	2.2
GTEx	Pituitary	8	0.72	2.3
GTEx	Prostate	9	1.08	2.5
GTEx	Skin Not Sun Exposed Suprapubic	16	0.65	2.4
GTEx	Skin Sun Exposed Lower leg	18	0.50	2.3
GTEx	Small Intestine Terminal Ileum	5	1.08	2.7
GTEx	Spleen	12	0.85	2.4
GTEx	Stomach	9	0.62	2.3
GTEx	Testis	15	0.48	2.2
GTEx	Thyroid	16	0.40	2.1
GTEx	Uterus	7	1.23	2.9
GTEx	Vagina	5	0.79	2.5
GTEx	Whole Blood	10	0.50	2.1
METSIM	Adipose	12	0.26	1.9
NTR	Blood	7	0.29	2.0
ROSMAP	Brain Pre-frontal Cortex	13	0.30	2.0
YFS	Blood	5	0.11	1.8
CommonMind	Brain Pre-frontal Cortex	10	0.19	2.0
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	3	0.18	2.1
The Cancer Genome Atlas	Breast Invasive Carcinoma	10	0.23	1.9
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	3	0.27	2.0
The Cancer Genome Atlas	Colon Adenocarcinoma	4	0.19	2.1
The Cancer Genome Atlas	Esophageal Carcinoma	4	0.59	2.4
The Cancer Genome Atlas	Glioblastoma Multiforme	6	0.59	2.1
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	13	0.48	2.1
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	12	0.29	1.9
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	6	0.29	2.0
The Cancer Genome Atlas	Brain Lower Grade Glioma	13	0.30	1.9
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	5	0.45	1.9
The Cancer Genome Atlas	Lung Adenocarcinoma	9	0.31	2.0
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	5	0.20	2.0
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	5	0.32	2.1
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	4	0.24	2.0
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	6	0.45	2.0
The Cancer Genome Atlas	Prostate Adenocarcinoma	13	0.28	2.0
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.29	2.1
The Cancer Genome Atlas	Soft Tissue Sarcoma	4	0.38	2.1
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.19	1.7
The Cancer Genome Atlas	Stomach Adenocarcinoma	6	0.36	2.1
The Cancer Genome Atlas	Testicular Germ Cell Tumors	4	0.31	1.8
The Cancer Genome Atlas	Thyroid Carcinoma	13	0.25	1.9
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.39	2.1